- Home
- RNTX vs COCH Comparison
RNTX vs COCH Comparison
Compare RNTX & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNTX
- COCH
- Stock Information
- Founded
- RNTX 2001
- COCH 1995
- Country
- RNTX United States
- COCH United States
- Employees
- RNTX N/A
- COCH N/A
- Industry
- RNTX Biotechnology: Pharmaceutical Preparations
- COCH Blank Checks
- Sector
- RNTX Health Care
- COCH Finance
- Exchange
- RNTX Nasdaq
- COCH Nasdaq
- Market Cap
- RNTX 26.5M
- COCH 25.2M
- IPO Year
- RNTX N/A
- COCH N/A
- Fundamental
- Price
- RNTX $1.34
- COCH $1.23
- Analyst Decision
- RNTX Hold
- COCH Strong Buy
- Analyst Count
- RNTX 1
- COCH 2
- Target Price
- RNTX N/A
- COCH $9.25
- AVG Volume (30 Days)
- RNTX 65.2K
- COCH 757.7K
- Earning Date
- RNTX 08-14-2025
- COCH 07-31-2025
- Dividend Yield
- RNTX N/A
- COCH N/A
- EPS Growth
- RNTX N/A
- COCH N/A
- EPS
- RNTX N/A
- COCH N/A
- Revenue
- RNTX N/A
- COCH $222,000.00
- Revenue This Year
- RNTX N/A
- COCH $2.11
- Revenue Next Year
- RNTX N/A
- COCH $24.86
- P/E Ratio
- RNTX N/A
- COCH N/A
- Revenue Growth
- RNTX N/A
- COCH N/A
- 52 Week Low
- RNTX $1.04
- COCH $1.06
- 52 Week High
- RNTX $4.40
- COCH $3.99
- Technical
- Relative Strength Index (RSI)
- RNTX 49.84
- COCH 39.84
- Support Level
- RNTX $1.06
- COCH $1.06
- Resistance Level
- RNTX $1.21
- COCH $1.22
- Average True Range (ATR)
- RNTX 0.10
- COCH 0.11
- MACD
- RNTX 0.02
- COCH -0.01
- Stochastic Oscillator
- RNTX 66.67
- COCH 35.42
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.